78 results about "Maximum dose" patented technology

Minimizing improper dosage of a drug admixture (including a single primary drug component and at least one second drug component). For each drug component in the drug admixture, receiving a name of the drug component along with its dosage unit, a maximum dose warning level and a maximum concentration warning level. Receiving a concentration for each of the single primary drug component and the at least one secondary drug component; and a dose setting of only the primary drug component. Automatically calculating a dose of each of the at least one secondary drug component. Generating an alert when: (i) the received dose setting of the primary drug component or calculated dose setting of the at least one secondary drug component exceeds the dose warning level; or (ii) the received concentration of the primary drug component or the at least one secondary drug component exceeds the concentration warning level.

A drug infusion system capable of delivering a fluid medication to a patient under direction of a medical professional continually at a basal rate and at an interval rate in each of a plurality of time slots over a specified period of time. The total dose of the fluid medication to be delivered to the patient over the period of time based on the basal rate and the interval rate for each of the plurality of time slots is determined, compared the total dose against a maximum dose. The basal rate is adjusted, if necessary, so that the total dose does not exceed the maximum dose.

A method of delivering a fluid medication to a patient under direction of a medical professional continually at a basal rate and at an interval rate in each of a plurality of time slots over a specified period of time. The total dose of the fluid medication to be delivered to the patient over the period of time based on the basal rate and the interval rate for each of the plurality of time slots is determined, compared the total dose against a maximum dose. The basal rate is adjusted, if necessary, so that the total dose does not exceed the maximum dose.

A radiation sensor array is carried on a flexible sheet of film, for placement on the skin of a patient adjacent to a brachytherapy location beneath the skin. With the array approximately centered on a position where radiation source to skin distance is estimated to be minimum, the array of sensors is used to monitor radiation dose received at the skin. With a controller connected to the array and preferably also to the radiation source in the applicator, the radiation dose received at all skin points of interest can be monitored, a point of maximum dose and a projected approach to limit dose can be calculated, and in response the system can warn the operator or control a brachytherapy procedure so as to discontinue radiation or control the radiation level or source position in real time. The system can also include percutaneous sensors.

The invention relates to the technical field of medicine, in particular to a new application of scutellarin, and provides the application of the scutellarin in preparing medicine for reducing pathological changes of kidney tissue and the application of the scutellarin in preparing medicine for treating nephritis. The new application of the scutellarin is proved by experiments to show that the intragastric administration is continuously performed on nephritis model rats with the scutellarin in the dose of 20 mg/kg and 40 mg/kg for eight weeks, the proteinuria of the model animals can be obviously reduced, hypoproteinemia, hyperlipidemia and the hypercoagulable state of blood can be corrected, the serum lipid peroxidation product content of the model rats can be lowered, the expression of TNF-alpha in the kidney tissue can be inhibited, and a protection effect on the kidney tissue and a good improvement effect on the kidney function are achieved; in addition, the maximum dose of intragastric administration on the rats is equal to and more than 18 g/kg, and obvious acute toxicity reaction and death do not occur on the animals.

With the objective of evaluating whether a dose is excessive for a subject, such a dose that image noise reaches less than or equal to a predetermined value is estimated upon an axial scan on the basis of projection data acquired by a scout scan. The dose is set as a maximum dose. An area other than air, of an image obtained by the axial scan is partitioned into a plurality of small areas i. Image noises N(i) at the respective small areas i are calculated. A warning image G1 in which all of pixel values of pixels in small areas in which the image noises N(i) are less than or equal to a predetermined value, are substituted with pixel values expressed in black level, is created and displayed.

A composition and method of treatment of neuromuscular, neuromuscular degenerative, neurodegenerative, autoimmune, developmental, traumatic, hearing loss related, and/or metabolic diseases, including spinal muscular atrophy (SMA) syndrome (SMA1, SMA2, SMA3, and SMA4, also called Type I, II, III and IV), traumatic brain injury (TBI), concussion, keratoconjunctivitis sicca (Dry Eye Disease), glaucoma, Sjogren's syndrome, rheumatoid arthritis, post-LASIK surgery, anti-depressants use, Wolfram Syndrome, and Wolcott-Rallison syndrome. The composition is selected from the group consisting of 2,3-DNP, 2,4-DNP, 2,5-DNP, 2,6-DNP, 3,4-DNP, or 3,5-DNP, bipartite 2,3-dinitrophenol, 2,4-dinitrophenol, 2,5-dinitrophenol, 2,6-dinitrophenol, 3,4-dinitrophenol, or 3,5-dinitrophenol (2,3-DNP, 2,4-DNP, 2,5-DNP, 2,6-DNP, 3,4-DNP, or 3,5-DNP) prodrugs; Gemini prodrugs, bioprecursor molecules, and combinations thereof. A dose of the composition for treatment of neurodegenerative diseases may be from about 0.01 mg/kg of body weight to about 50 mg/kg of body weight of the patient in need of treatment. A dose of the composition for treatment of metabolic diseases may be from about 1 mg/70 kg of body weight to about 100 mg/70 kg of body weight of the patient in need of treatment, and a maximum dose per day is about 200 mg/70 kg of body weight of the patient in need of treatment.

The invention discloses a method for obtaining a beam energy spectrum, and the method comprises the steps: setting the initial energy spectrum distribution of a beam; calculating the dose distribution on a central axis of the beam based on the initial energy spectrum distribution; judging whether a calculated depth value of a maximum dose place and the dose value of the maximum dose place are matched with the measurement value of dose distribution on the central axis of the beam or not: enabling the current energy spectrum distribution to serve as the energy spectrum distribution of the beam if the calculated depth value and the dose value are matched with the measurement value, or else, adjusting the current energy spectrum distribution, and calculating the dose distribution on the central axis of the beam based on the adjusted energy spectrum distribution till the calculated depth value and the dose value are matched with the measurement value. The method is simple and effective.

The invention discloses a radiotherapy system and a treatment plan generation method thereof. The radiotherapy system comprises a beam irradiation device, a treatment plan module and a control module. The beam irradiation device generates a treatment beam and irradiates an irradiated body to form an irradiated part, the treatment plan module generates a treatment plan according to parameters of the treatment beam and medical image data of the irradiated part, and the control module calls the treatment plan corresponding to the irradiated body from the treatment plan module, and controls the beam irradiation device to sequentially irradiate the irradiated body according to the at least two irradiation angles determined by the treatment plan generation method and the irradiation time corresponding to each irradiation angle. According to the radiotherapy system and the treatment plan generation method thereof, the radiation quantity of the shallow part of the irradiated part can be dispersed, and the radiation quantity of the deep part of a lesion tissue can be increased, so that the maximum dose of a normal tissue can be reduced, the minimum dose of the lesion tissue can be increased, and uniform distribution of the dose in the lesion tissue can be ensured.

The invention discloses low-medium level radioactive waste barrel surface dose rate detection equipment and an application thereof, and relates to the technical field of nuclear power station solid waste treatment. The equipment comprises a waste bin rotating assembly, a waste bin surface dose rate detection device and a waste bin surface activity measurement device; the waste bin surface dosage rate detection device comprises a lifting support assembly, a lifting power assembly and a mechanical arm assembly. The mechanical arm assembly comprises a limiting transmission sliding block, a mechanical arm upper arm, an electric telescopic rod, a mechanical arm lower arm, an upper and lower arm torsional elastic piece, a detector assembly and a detector position adjusting elastic part. A dose rate detection device is arranged on one side, far away from the mechanical arm lower arm, of the detector assembly; rollers are respectively arranged at two ends of one side, far away from the mechanical arm lower arm, of the detector assembly; the dose rate distribution, maximum dose rate detection and activity detection of different heights and distances of the waste bin are implemented by adopting one detector assembly, so the use is very convenient.

The present invention relates to a drive mechanism which is suitable for an injection device (1; 101; 201; 301; 401), especially a pen type drug delivery device. The mechanism comprises a housing (4; 104; 204; 304; 404), a dosing member (7; 107; 206; 306; 407), which during dose setting, dose resetting and dose dispensing rotates relative to the housing between a zero dose position and a maximum dose position, and an insert (5; 126; 205; 307; 431) which is rotationally constrained to the housing. The dosing member (7; 107; 206; 306; 407) and the insert (5; 126; 205; 307; 431) each comprise at least one abutment feature (22, 24; 122, 24; 222; 422, 424) contacting each other when the dosing member (7; 107; 206; 306; 407) reaches its zero dose position during dose dispensing, wherein an audible and/or tactile feedback is generated by the contact of the abutment features (22, 24; 122, 124; 222; 422, 424).

Provided are a method and system for proving a drug delivery device having a variable maximum dose. The drug delivery device comprising a first tubular member (260) and a second tubular member (300) rotatably coupled to the first tubular member (260). A maximum stop component (286a, b) is operatively coupled to the first tubular member (260) and the second tubular member (300) such that the maximum stop component (286a, b) is movable from a first position to a second position. The first position defines a first maximum dose that may be set by a user of said drug delivery device and the second position defines a second maximum dose that may be set by the user of said drug delivery device.